Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

Covid-19 roundup: Sci­en­tists pull pre-print with in­flat­ed in­ci­dence of my­ocardi­tis post mR­NA vac­cine; As­traZeneca seeks EUA for long-act­ing an­ti­body

Cana­di­an sci­en­tists re­cent­ly with­drew an alarm­ing pre-print man­u­script that mis­tak­en­ly said the in­ci­dence of the heart con­di­tion my­ocardi­tis was a lot more fre­quent than ac­tu­al­ly iden­ti­fied fol­low­ing vac­ci­na­tion with ei­ther Mod­er­na’s or Pfiz­er’s mR­NA shot.

“In or­der to avoid mis­lead­ing ei­ther col­leagues or the gen­er­al pub­lic and press, we the au­thors unan­i­mous­ly wish to with­draw this pa­per on the grounds of in­cor­rect in­ci­dence da­ta. We thank the many peer re­view­ers who went out of their way to con­tact us and point out our er­ror. We apol­o­gize to any­one who may have been up­set or dis­turbed by our re­port,” they wrote in an up­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.